Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Items 401–500 of 597
Licata, A., Russo, G. T., Giandalia, A., Cammilleri, M., Asero, C., & Cacciola, I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030558 · Cited by 14
Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells
Caporarello, N., Parrino, C., Trischitta, V., & Frittitta, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181190 · Cited by 13
Zhang, Y., Chen, Y., Cheng, J., Guo, Z., Lu, Y., & Tian, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.048 · Cited by 13
New Therapeutic Agents for Diabetes Mellitus: Implications for Anesthetic Management
Chen, D., Lee, S. L., & Peterfreund, R. A. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819dcc51 · Cited by 12
Üçkaya, G., Delagrange, P., Chavanieu, A., Grassy, G., Berthault, M., Ktorza, A., Cerasi, E., Leibowitz, G., & Kaiser, Ν. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05818 · Cited by 12
“Furthermore, GLP-1/ exendin 4 treatment may also increase -cell mass by suppressing -cell apoptosis (Li et al. 2003).”
BackgroundHyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?
Barbetti, F., Colombo, C., Haataja, L., CRAS-MÉNEUR, C. M. H., Bernardini, S., & Arvan, P. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0029-5 · Cited by 14
“First, we tested the effects of exendin-4, a GLP-1 analogue that is thought to help stimulate insulin secretion while suppressing glucagon secretion [27–30].”
BackgroundMethodDreams for Type 1 Diabetes: Shutting Off Autoimmunity and Stimulating β-Cell Regeneration
Weir, G. C., & Bonner‐Weir, S. (2010) · Endocrinology · doi:10.1210/en.2010-0538 · Cited by 12
Molecular Basis of cAMP Signaling in Pancreatic β Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_25 · Cited by 12
“These findings need to be substantiated, but it is of interest that prior in vivo studies of rodents or in vitro studies of human islets demonstrate that GLP-1R agonists enhance β-cell neogenesis, proliferation, and survival (Xu et al. 1999; Tourrel et al. 2001; Li et al. 2003; Farilla et al. 2003).”
BackgroundGLP-1(28-36)amide, a Long Ignored Peptide Revisited
Huang, K., Zhou, B., Ji, K., Peng, A., & Yang, X. (2014) · The Open Biochemistry Journal · doi:10.2174/1874091x01408010107 · Cited by 11
Nishimura, R., Ushiyama, A., Sekiguchi, S., Fujimori, K., Ohuchi, N., Satomi, S., & Goto, M. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.01.047 · Cited by 9
The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology
Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 14
Han, J. D. J., Meng, T., Chen, X., Han, Y., Fu, J., Zhou, F. L., Fei, Y., & Li, C. (2019) · The FASEB Journal · doi:10.1096/fj.201801479r · Cited by 11
Crutchlow, M. F., Yu, M. D., Bae, Y., Deng, S. L., & Stoffers, D. A. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.03.161 · Cited by 13
Drug Insight: new immunomodulatory therapies in type 1 diabetes
Cernea, S., & Herold, K. C. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0082 · Cited by 13
“In animal models, exendin 4 was shown to decrease β-cell apoptosis and increase β-cell proliferation”
BackgroundSong, X., Sun, X., Hao, H., Han, Q., Han, W., & Mu, Y. (2021) · Stem Cells and Development · doi:10.1089/scd.2020.0137 · Cited by 11
Östenson, C., Matthaei, S., Reaney, M. D., Krarup, T., Guerci, Kiljanski, Salaun-Martin, Sapin, Bruhn, Mathieu, C., et al. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s41827 · Cited by 10
Rydgren, T., Börjesson, A., Carlsson, A., & Sandler, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.011 · Cited by 10
Translational implications of the β-cell epigenome in diabetes mellitus
Johnson, J. S., & Evans‐Molina, C. (2014) · Translational research · doi:10.1016/j.trsl.2014.03.002 · Cited by 10
GLP-1 signaling and the regulation of pancreatic β-cells mass/function
Buteau, J. (2011) · Avances en Diabetología · doi:10.1016/s1134-3230(11)70002-3 · Cited by 14
Luo, Y., Ru, Y., Zhao, H., Liu, L., Hong, S., Sun, X., Kuai, L., Lü, Y., Xing, M., Chen, X., et al. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/6419509 · Cited by 10
“Half-fat diet was used to induce obesity and insulin resistance in mice [21], and intraperitoneal injection of a chain urea toxin (STZ) was applied to destruct pancreatic islet β cells in the mice [22], thus generating a condition similar to human type II diabetes.”
MethodInvestigational agents that protect pancreatic islet β-cells from failure
Aston‐Mourney, K., Proietto, J., & Andrikopoulos, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.10.1241 · Cited by 11
“The treatment of animal models of Type 2 diabetes, such as the Goto–Kakizaki (GK), the db/db diabetic mouse and the Zucker diabetic fatty (ZDF) rat, with GLP-1 has been associated with increased β-cell mass and protection from apoptosis [80-82] Furthermore, GLP-1 agonists and inhibitors of DPP-IV have been shown to pr…”
MethodHarkavyi, A., Rampersaud, N., & Whitton, P. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407152 · Cited by 14
“Additionally, EX-4 protects beta cells from cytotoxic insults [7] and also promotes their proliferation and neogenesis from precursors [8, 9].”
BackgroundGiorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 11
Tsunekawa, S., Miura, Y., Yamamoto, N., Itoh, Y., Ariyoshi, Y., Senda, T., Oiso, Y., & Niki, I. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01909 · Cited by 10
Gene-Altered Islets for Transplant: Giant Leap or Small Step?
Harlan, D. M. (2004) · Endocrinology · doi:10.1210/en.2003-1392 · Cited by 10
Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation
Chae, H. Y., Kang, J. G., Kim, C. S., Lee, S. J., Lee, M., Kang, D., Jun, H., & Ihm, S. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01394.x · Cited by 9
“The GLP-1 dose that promoted b-cell growth in rodents was 50–100 lg/kg body weight (BW), while the tolerable dose in humans is <2 lg/kg BW [26–28].”
BackgroundRenal posttransplantation diabetes mellitus: An overview
Pimentel, A. L., Bauer, A. C., & Camargo, J. L. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.09.010 · Cited by 13
Tian, H., Chang, M., Lyu, Y., Dong, N., Yu, N., Yin, T., Zhang, Y. X., He, H., Gou, J., & Tang, X. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2305110 · Cited by 10
Sahraoui, A., Winzell, M. S., Gorman, T., Smith, D. M., Skrtic, S., Høyem, M., Abadpour, S., Johansson, L., Korsgren, O., Foss, A. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121204 · Cited by 9
“Accordingly, the apparent increase in beta cell number seems to be a consequence of an anti-apoptotic effect of exendin-4 protecting the transplanted graft which several studies have demonstrated [21–24], and our observations are consistent with these.”
ResultLuo, L., & JACKSON, I. M. D. (2007) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 9
Glucagon-like peptide analogues for type 2 diabetes mellitus
Snaith, A., McIntyre, L., Rothnie, H. M., Thomas, S., Royle, P., & Waugh, N. R. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423 · Cited by 9
Re-Expression of IGF-II Is Important for Beta Cell Regeneration in Adult Mice
Zhou, L., Pelengaris, S., Abouna, S., Young, J., Epstein, D. B. A., Herold, J., Nattkemper, T. W., Nakhai, H., & Khan, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043623 · Cited by 8
“Some encouraging therapeutic results have been obtained by administering thiazoledenediones or GLP-1 analogues to various diabetes models [1,2] and also in man [3,4].”
BackgroundNew Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats
Reusch, C. E., & Padrutt, I. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2012.11.003 · Cited by 9
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 9
Campbell, S. A., Hubert, M., Johnson, J., Salamon, N., & Light, P. E. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1902069 · Cited by 8
Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid
Fernandes, M. F., Tomczewski, M. V., & Duncan, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084163 · Cited by 8
Beltrand, J., Colomb, V., Marinier, É., Daubrosse, C., Alison, M., Burcelin, R., Cani, P. D., Chevenne, D., & Levy-marchal, C. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e3181559d5c · Cited by 11
Neonatal Pig Liver–Derived Progenitors for Insulin-Producing Cells: An In Vitro Study
Racanicchi, L., Basta, G., Montanucci, P., Guido, L. G., Pensato, A., Conti, V., & Calafiore, R. (2007) · Tissue Engineering · doi:10.1089/ten.2007.0098 · Cited by 9
Preserving insulin secretion in Type 2 diabetes mellitus
Tibaldi, J. M. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.147 · Cited by 11
Wang, J., Wang, F., Xu, J., Ding, S., & Guo, Y. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.006 · Cited by 9
“[2] Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.”
BackgroundGlucagon-Like Peptide 1 and Type 1 Diabetes: NOD Ready for Prime Time?
Hadjiyanni, I., & Drucker, D. J. (2007) · Endocrinology · doi:10.1210/en.2007-1112 · Cited by 8
Self-citationSimonsen, L., Pilgaard, S., Ørskov, C., Hartmann, B., Holst, J. J., & Deacon, C. F. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01066.x · Cited by 9
Halter, J. B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-378638-8.00017-8 · Cited by 9
Hahm, E., Lee, Y. S., & Jun, H. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346367 · Cited by 8
Jin, M., Shen, G., Jin, Y., Sun, H., Xing, Z., Zhang, Y., Lee, D., Cui, Y., Yu, L., Kim, J., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11279 · Cited by 8
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Uhles, S., Wang, H., Benardeau, A. M., Prummer, M., Brecheisen, M., Sewing, S., Tobalina, L., Bosco, D., Wollheim, C. B., Migliorini, C., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01352.x · Cited by 9
R-spondin1 Deficiency Enhances β-Cell Neogenesis in a Murine Model of Diabetes
Chahal, J. K., Wong, V. S. C., Chaboissier, M., & Brubaker, P. L. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a70bfb · Cited by 7
Glucagon-like peptide-1(1–37) can enhance blood glucose homeostasis in mice
Zhao, L., Ye, H., Li, D., Lao, X., Li, J., Wang, Z., Xiao, L., Wu, Z., & Huang, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.010 · Cited by 7
Zheng, J.-X., Xiao, Y.-C., Hu, Y., Hao, M., & Kuang, H. (2014) · Andrologia · doi:10.1111/and.12252 · Cited by 9
“…for its promising activities of glycaemic control, inhibiting inappropriately high glucagon secretion, stimulating insulin secretion, protecting against b-cell apoptosis via engagement of antiapoptotic pathway, promoting b-cell proliferation and inducing weight loss (Li et al., 2003; Good, 2012).”
BackgroundUnger, J., & Moriarty, C. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.07.004 · Cited by 9
Winzell, M. S., & Åhrén, B. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0121 · Cited by 7
Jessen, L., & D’Alessio, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.013 · Cited by 7
Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management
Chaudhry, M., & Sif, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01831-1 · Cited by 7
“More - over GLP-1RA’s exert cytoprotective effects on pancreatic β-cells by inhibiting apoptosis, promoting cell survival and sustaining insulin secretory capacity over time [130].”
Physiological Fatty Acid-Stimulated Insulin Secretion and Redox Signaling Versus Lipotoxicity
Ježek, P. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0799 · Cited by 9
Models for pharmacological activation of beta-cell regeneration in diabetes
Movassat, J., & Portha, B. (2007) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2007.11.006 · Cited by 6
Reprogramming gut and pancreas endocrine cells to treat diabetes
Tudurí, E., & Kieffer, T. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01446.x · Cited by 6
“Moreover, GLP-1 receptor signalling has been reported to stimulate neogenesis and proliferation of β-cells, as well as inhibit their apoptosis [58,59].”
BackgroundGojani, E. G., Wang, B., Li, D., Kovalchuk, O., & Kovalchuk, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010421 · Cited by 9
Gu, N., Cho, S., Kim, J. W., Shin, D., Seol, E., Lee, H., Lim, K. S., Shin, S., Jang, I., & Yu, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.002 · Cited by 7
Hamamatsu, K., Fujimoto, H., Fujita, N., Murakami, T., Shiotani, M., Toyoda, K., & Inagaki, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-54722-w · Cited by 7
Akiyama, S., Ogiwara, T., Aoki, T., Tsunekawa, K., Araki, O., & Murakami, M. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.09.004 · Cited by 6
“GLP-1 affects β-cells by amplifying glucose-induced insulin secretion, promoting proliferation, and inhibiting apoptosis (Li et al., 2003; Baggio and Drucker, 2007).”
BackgroundBaden, M. Y., Fukui, K., Hosokawa, Y., Iwahashi, H., Imagawa, A., & Shimomura, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144606 · Cited by 7
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
Special Features: Incretin-based therapies in type 2 diabetes mellitus
Cw, C., Jm, E., Chia, C. W., Egan, J. M., correspondence, A., & Egan, J. M. (2014) · Cited by 6
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
Is there U-turn from Insulin Back to Pills in Diabetes?
Ertek, S., & Çetinkalp, Ş. (2014) · Current Vascular Pharmacology · doi:10.2174/15701611113119990122 · Cited by 5
“GLP-1R agonists has been associated with expansion of -cell mass via stimulation of -cell proliferation, promotion of islet cell neogenesis, and inhibition of -cell apoptosis in animal studies [60,61].”
BackgroundGhanaat‐Pour, H., & Sjöholm, Å. (2011) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000102 · Cited by 5
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Campbell, S. A., Light, P. E., & Simpson, S. H. (2019) · Diabetic Medicine · doi:10.1111/dme.14154 · Cited by 5
Dong, Y., Yin, J., Zhang, Y., & Chen, J. D. Z. (2021) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13367 · Cited by 5
GLP‐1 C‐terminal structures affect its blood glucose lowering‐function
Li, Y., Shi, C., Lv, Q.-J., Zhang, H., Biehu, L., Bian, G., Huang, Q., Zhang, W., Xue, X., Ren, X., et al. (2008) · Journal of Peptide Science · doi:10.1002/psc.997 · Cited by 5
Self-citationGrowth Factor Mediated Regulation of Beta Cell Survival
Vasavada, R. C. (2010) · The Open Endocrinology Journal · doi:10.2174/1874216501004010078 · Cited by 6
“MLDS C57Bl6 male mice exendin-4 -cell death [48]”
BackgroundMethodInfluentialNauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
“E nh an ce d βce ll ap op to si s [1 93 ] In hi bi tio n of β -c el l a po pt os is e Y es [ 63 , 2 13 ] Y es [ 23 3] Y es [ 23 4] Pr ob ab le Pr ob ab le”
BackgroundRecent progress of remission in type 2 diabetes
Zhao, Z., Yue, H., Zhang, X., Chen, F., Xu, J., & Shao, S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251408210 · Cited by 4
Zhao, Y., Jing, W., Li, L., Zhao, S., & Yamasaki, M. (2023) · Mathematical Biosciences · doi:10.1016/j.mbs.2023.109090 · Cited by 5
Chae, H. Y., Lee, M., Hwang, H. J., Kim, H. A., Kang, J. G., Kim, C. S., Lee, S. J., & Ihm, S. (2013) · Transplant International · doi:10.1111/tri.12052 · Cited by 4
Unger, J., & Parkin, C. G. (2009) · Insulin · doi:10.1016/s1557-0843(09)80029-8 · Cited by 5
GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Montoya, P. A., Evelyn, B., Folino, C., & Allo, Y. J. M. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201124123549 · Cited by 4
Negi, V., Lee, J., Mandi, V., Danvers, J., Liu, R., Perez-Garcia, E. M., Li, F., Jagannathan, R., Yang, P., Filingeri, D., et al. (2024) · Cells · doi:10.3390/cells13131108 · Cited by 5
“GLP-1 receptor agonists have been shown to protect β -cells from cytokine-induced apoptosis and improve β -cells’ proliferation and function [6–8].”
BackgroundMechanisms of Beta-Cell Death in Diabetes
Donath, M. Y., & Ehses, J. A. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_5 · Cited by 5
Matuszek, B., Lenart-Lipińska, M., & Nowakowski, A. M. (2008) · PubMed · Cited by 7
Pancreatic β-Cell Mass as a Pharmacologic Target in Diabetes
Hanley, S. C. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v12i2.267 · Cited by 5
Enhanced Gene Transfer to Pancreatic Islets Using Glucagon-Like Peptide-1
Lee, B., Kim, M.-H., Chae, H. Y., Hwang, H.-J., Kang, D., & Ihm, S. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.10.040 · Cited by 4
Chayosumrit, M. (2011) · The Open Stem Cell Journal · doi:10.2174/1876893801103010011 · Cited by 4
“GLP-1 also increased cell survival and reduced caspase activation in baby hamster kidney (BHK) fibroblasts expressing a transfected GLP-1R [5].”
InfluentialGastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis
Drucker, D. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50009-x · Cited by 5
Self-citationGlucagon-Like Peptide-1 and Diabetes 2012
Monami, M., Pasquale, G. D., Rowzee, A. M., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/768760 · Cited by 5
Regenerative Medizin und stammzellbasierte Wirkstoffentwicklung
Sakurada, K., McDonald, F. M., & Shimada, F. (2008) · Angewandte Chemie · doi:10.1002/ange.200700724 · Cited by 4
Luo, J. Z. Q., Vang, S., Zhao, T. C., JACKSON, I. M. D., & Luo, L. (2014) · InTech eBooks · doi:10.5772/57550 · Cited by 3
Saghahazrati, S., Ayatollahi, S. A., Kobarfard, F., & Minaei, B. (2019) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.85247 · Cited by 3
The Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
Wasniewska, M. G., Arrigo, T., Crisafulli, G., Aversa, T., Messina, M., Salzano, G., & Luca, F. D. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346368 · Cited by 3
Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular
Pi-Sunyer, X. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)73556-8 · Cited by 3
Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2
Puig‐Domingo, M., & Reviriego, J. (2007) · Revista Clínica Española · doi:10.1157/13107949 · Cited by 4
Effects of Vagotomy and Fenugreek on Hyperlipidemia and Insulin Resistance
Khound, R. (2017) · Lincoln (University of Nebraska) · Cited by 3
Microencapsulation of Pancreatic Islets : A Non-Vascularised Transplantation Model
Bohman, S. (2008) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 3
Ravasio, R. (2008) · Giornale Italiano di Health Technology Assessment · doi:10.1007/bf03320710 · Cited by 3
VATSAVAYI, J. R., & Nalanda, R. B. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i5.51095 · Cited by 2
Yavuzkır, Ş., Cinar, D. K., Çınar, A., Bildirici, F., & Aydın, S. (2025) · Diagnostics · doi:10.3390/diagnostics15192439 · Cited by 2
JNK3 regulates β cell responses to incretins in human islets and mouse models
Louzada, R. A. N., Medina, M. G., Pita-Grisanti, V., Bouvière, J., Neves, A. F., Almaça, J., Han, M. S., Davis, R. J., Leibowitz, G., Blandino-Rosano, M., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci185707 · Cited by 2
Incretin Therapy and Beta Cell Function
Goundan, P. N., UNDERWOOD, P. C., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.006 · Cited by 2
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.